Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Stephen L HauserAnne H CrossKevin WinthropHeinz WiendlJacqueline NicholasSven G MeuthPaul S GiacominiFrancesco SaccàLinda MancioneRonald ZielmanMorten BaggerAyan Das GuptaDieter A HäringValentine JehlBernd C KieseierRatnakar PingiliDee StonemanWendy SuRoman WilliLudwig KapposPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
In patients with up to 3.5 years' exposure, ofatumumab was well tolerated, with no new safety risks identified. These findings, with its established effectiveness, support a favorable benefit-risk profile of ofatumumab in RMS.